Cytek Biosciences (NASDAQ: CTKB) net income
Cytek Biosciences reported a net loss of $66.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $6.0m.
Cytek Biosciences's best year of the last 6 was fiscal 2020. The biggest drop was in fiscal 2021, −84.4%. It reported a loss in 3 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$66.5m | — | −33.0% | — |
| 2024 | −$6.0m | — | −3.0% | — |
| 2023 | −$12.1m | −589.0% | −6.3% | −$0.09 |
| 2022 | $2.5m | −17.9% | 1.5% | $0.02 |
| 2021 | $3.0m | −84.4% | 2.4% | $0.00 |
| 2020 | $19.4m | — | 20.9% | $0.11 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Cytek Biosciences net income compared with its sector
By net income for its latest fiscal year, Cytek Biosciences ranks 288th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Cytek Biosciences, −33.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 286th | Tarsus Pharmaceuticals | −$66.4m | −14.7% |
| 287th | Compass Therapeutics | −$66.5m | — |
| 288th | Cytek Biosciences | −$66.5m | −33.0% |
| 289th | Ocugen | −$67.8m | −1,537.4% |
| 290th | Zura Bio | −$68.7m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Cytek Biosciences
- How much did Cytek Biosciences earn in fiscal 2025?
- Cytek Biosciences reported a net loss of $66.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $6.0m.
- What was the most profitable year for Cytek Biosciences?
- Of its last 6 fiscal years, fiscal 2020, with $19.4m.
- Where does Cytek Biosciences rank in its sector by net income?
- It ranks 288th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Cytek Biosciences come from?
- From the annual report (Form 10-K) that Cytek Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Cytek Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Cytek Biosciences: the Cytek Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.